CELZ

Creative Medical Technology Holdings, Inc.
CAPPED RATING

Creative Medical Technology Holdings, Inc. (CELZ) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D-). The rating has held at C- for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
D+
Factor Score 1.8 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.7
EV / EBITDA 0.8
Rev Growth YoY N/A
Gross Margin 66.9%
Price Return 3M -49.9%
Price Return 12M -80.1%
Catalyst Signal 0.00
Market Cap $4.6M
TTM Revenue $3.0K
Price / Sales 1.5K
ROE -77.9%

Historical Factor Score Progression

Held C- for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 D+ (1.8) C (2.3) C- (2.0) D- (1.0) C+ (2.6) C- (1.9)
2026-11-04 D+ (1.8) C (2.3) C- (2.0) C- (2.0) C+ (2.7) C- (2.1)
2026-10-28 D+ (1.8) C (2.2) C- (2.0) C- (1.9) C+ (2.7) C- (2.1)
2026-10-21 D+ (1.8) C (2.2) C- (2.0) D+ (1.7) C+ (2.6) C- (2.1)
2026-10-14 D+ (1.8) C (2.2) C- (2.0) C- (1.9) C+ (2.6) C- (2.1)
Page 1 of 4